72.40
전일 마감가:
$70.85
열려 있는:
$71.17
하루 거래량:
29,946
Relative Volume:
0.35
시가총액:
$77.49M
수익:
$7.10M
순이익/손실:
$-39.43M
주가수익비율:
-77.02
EPS:
-0.94
순현금흐름:
$-46.50M
1주 성능:
-6.64%
1개월 성능:
-10.14%
6개월 성능:
-86.68%
1년 성능:
-90.34%
스프루스 바이오 Stock (SPRB) Company Profile
명칭
Spruce Biosciences Inc
전화
(415) 655-4168
주소
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
SPRB
Spruce Biosciences Inc
|
72.40 | 75.84M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
스프루스 바이오 Stock (SPRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-03-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 개시 | Guggenheim | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | The Benchmark Company | Speculative Buy |
| 2021-11-16 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 개시 | H.C. Wainwright | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Credit Suisse | Outperform |
| 2020-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2020-11-03 | 개시 | SVB Leerink | Outperform |
모두보기
스프루스 바이오 주식(SPRB)의 최신 뉴스
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks
Experimental enzyme therapy stabilizes skills for 6 years in fatal disorder - stocktitan.net
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - BioSpace
Spruce Biosciences Makes Two SVP Appointments - Contract Pharma
Spruce Biosciences (NASDAQ:SPRB) Shares Up 0.6%Time to Buy? - MarketBeat
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - BioSpace
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium - Investing News Network
Harbour BioMed Exercises Warrant to Acquire 3.8% of Spruce Biosciences Inc. - intellectia.ai
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Harbour BioMed Acquires Stake in U.S. Partner Spruce Biosciences, Signaling Strategic Shift in Chinese Biotech - IndexBox
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership - intellectia.ai
Harbour BioMed Expands Stake in Spruce Biosciences (SPRB) - GuruFocus
Harbour BioMed Exercises Agreement to Buy Spruce Biosciences Common Stock - Contract Pharma
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences (SPRB) - Intellectia AI
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences - Intellectia AI
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deep - GuruFocus
Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences - Nasdaq
HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise - TipRanks
Harbour BioMed buys into Spruce to back new hormone disorder drug - Stock Titan
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Barchart.com
Harbour BioMed takes stake in Spruce Biosciences - MSN
HBM Lifts Spruce Biosciences Stake to About 3.8% After Warrant Exercise - marketscreener.com
Spruce Biosciences (SPRB) Price Target Increased by 10.02% to 235.11 - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace
Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - marketscreener.com
Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets
Spruce Biosciences (SPRB) price target increased by 55.76% to 213.69 - MSN
MSN Money - MSN
Spruce Biosciences assumed with a buy at HC Wainwright - MSN
Spruce Biosciences (NASDAQ:SPRB) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Equities Analysts Offer Predictions for SPRB FY2025 Earnings - MarketBeat
Spruce Biosciences initiated with an Outperform at Oppenheimer - Yahoo Finance
Oppenheimer Initiates Coverage on SPRB with "Outperform" Rating - GuruFocus
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Yahoo Finance
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength - TradingView — Track All Markets
Oppenheimer initiates coverage on Spruce Biosciences stock with Outperform rating - Investing.com Australia
Oppenheimer Initiates Coverage of Spruce Biosciences (SPRB) with Outperform Recommendation - Nasdaq
Revenue per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView — Track All Markets
Spruce Biosciences stock rating resumed at Buy by H.C. Wainwright - Investing.com Nigeria
HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB) - MarketBeat
SPRB Stock: HC Wainwright & Co. Initiates Coverage with Buy Rati - GuruFocus
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P TMI Index - marketscreener.com
With Spruce Biosciences Stock Sliding, Have You Assessed The Risk? - Trefis
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences CEO reports RSU vesting and option repricing | SPRB SEC FilingForm 4 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail
스프루스 바이오 (SPRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):